Incidence of Invasive Aspergillosis and Its Relation to Galactomannan Clinical Outcomes

Incidence of Invasive Aspergillosis at Hospital H+ Querétaro and the Relationship Between Galactomannan and Clinical Outcomes

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07621263

Enrollment

150

Registered

2026-06-02

Start date

2022-03-01

Completion date

2026-03-31

Last updated

2026-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive Aspergillosis

Keywords

Galactomannan, Aspergillus spp, Bronchoalveolar Lavage, Clinical Outcomes

Brief summary

The goal of this observational study is to analyze the relationship between galactomannan index values and clinical outcomes , as well as to determine the annual and seasonal incidence of invasive aspergillosis in pediatric and adult patients with suspected or confirmed infection at Hospital H+ Querétaro. The main questions it aims to answer are: * Are high galactomannan levels significantly associated with adverse clinical outcomes, such as mortality and longer hospital stays, in immunocompromised patients? * How does the incidence of invasive aspergillosis vary annually and seasonally between March 2022 and March 2026? Researchers will compare patients with high galactomannan levels against those with low or negative levels to see if this biomarker can be used as a reliable tool to predict patient outcomes. The research team will: * Collect and review clinical files of patients who had a galactomannan test from bronchoalveolar lavage samples. * Record data on galactomannan levels, hospital stays, and patient recovery or complications.Identify risk factors and seasonal patterns of the infection.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients who underwent galactomannan determination testing in bronchoalveolar lavage (BAL) samples * Tests performed during the period from March 2022 to March 2026.

Exclusion criteria

* Patients with galactomannan tests performed outside the established period (March 2022 to March 2026). * Galactomannan tests performed using serum samples.

Design outcomes

Primary

Measure	Time frame	Description
Incidence of Invasive Aspergillosis and Association of Galactomannan Index with Clinical Outcomes	From March 2022 to March 2026	An analysis to determine the annual and seasonal incidence of Invasive Aspergillosis (IA) , alongside a quantitative evaluation of how Galactomannan (GM) index values relate to clinical outcomes in patients. The study will measure the association of GM levels with specific adverse endpoints, including patient mortality, length of hospital stay (estancia hospitalaria), intensive care unit (ICU) admission, and the development of clinical complications. Additionally, it will compare these clinical outcomes between patients with elevated GM levels against those with low or negative levels to evaluate GM's utility as a prognostic marker.

Countries

Mexico

Outcome results